In the News |
May 29, 2026
Safety Is The Mantra In Kivu Bioscience’s ADC Trials For Solid Tumors

A conversation between Kivu Bioscience CEO Mo Trikha and Clinical Leader Executive Editor Abby Proch In a
crowded antibody-drug conjugate (ADC) landscape, differentiation hinges on improving the fundamental
risk–benefit equation.